Cell line · CVCL_D615
Papers124
30 more articles give this line's RRID in its Methods without naming the line nearby, so they are not listed.
1 to 20 of 124
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Immunogenicity and structure of a stabilized HIV-1 clade C Env from a pediatric elite neutralizer in complex with an autologous bnAb. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of the Asn333 high-mannose N-glycan impairs ACP3 folding and drives disease-associated dysfunction. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Distinct mechanisms of neutralization by antibodies targeting a conserved pneumovirus F epitope. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Structural Mechanisms of DNAJC13 Dimeric Assembly and InsP6 binding in Recycling Endosome Regulation. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Potently neutralizing and protective human monoclonal antibodies against the measles fusion protein trimer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Age-related molecular IgE sensitization to indoor and outdoor respiratory allergens: a two-step cross-sectional study in Algeria and Türkiye. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Characterisation of a human monoclonal antibody targeting a conserved epitope at the base of the HA head of influenza A(H3N2) virus. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Canonical Antibodies Adopt Distinct Binding Modes to Recognize Viral Glycan Shields. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functionalizing Hydrogel Nanovials with Vesicles Mimicking Antigen-Presenting Vesicles and Cancer Exosomes Improves T Cell Capture and Activation. | ACS Nano | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cryo-EM structure of soluble VPS13C suggests its regulation by a conformational switch and by calmodulin. | Mol Cell | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Localized heme sensing through a ternary molecular glue. | bioRxiv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Development of human monoclonal antibodies against TARM1 by yeast display. | FEBS Open Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nucleoprotein and glycoprotein based serological assays for detection of Marburg virus infections. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Nasal RNA-scaffold-protein vaccine protects mice from human H5N1 clade 2.3.4.4b virus lethal infection and safeguards against vaccine-unmatched viruses. | EBioMedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving Anti-CTLA-4 Therapies through Peptide Masking and Fragment Crystallizable Non-fucosylation: Preclinical Characterization of Three Novel Antibodies. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities. | BMC Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Immunogenicity and protective efficacy of MERS CoV, NL140422, and HKU4 spike protein nanoparticle vaccines. | Npj Viruses | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_D615/papers